Jul. 3 at 4:33 PM
$BMEA the company might not dislike that the price is kept below
$2 until the underwriter option to purchase another 15% shares of the public offering (3.0M) expires on July 20. The good news is, this expiration is only 10 sessions away. I would expect the Icovamenib 52-week data to come out soon after, too. The current sell trend clearly is close to being exhausted, it will bottom out soon and a couple days of flat will be followed by further upside, just like the price action before June 3.